Strategic partnership

The alliance between Eli Lilly and GlycoFi

Overview

Eli Lilly and Company is a pharmaceutical firm owned by an American with its headquarters in Indiana. The company is on a quest to benefit a multitude of people around the globe daily through the provision of solutions that are feasible, enhanced medicine, and lifesaving (Lilly, 2020). Eli Lilly partake their quests through research, marketing and development of pharmaceutical treatments. For several years the pharmaceutical firm Eli Lilly, has been indulging in alliances with more than one hundred firms around the globe determined to marketing, growing, and finding new pharmaceutical treatment and make a better tomorrow by provision of instant satisfying relief that was not in existence.

One of the firms Eli Lilly has had an alliance with is GlycoFi. Glycofi is a personal, biotechnology business venture (Glycofi, 2020). GlycoFi is working round the clock to build a better tomorrow by developing protein optimization knowledge that will help in manufacturing, commercialize, and produce a new generation biotherapeutics.

Critical thinking discussion

Eli Lilly and GlycoFi first entered a wide, commercialized, tactical, and multiproduct alliance in 2005. The primary aim of finding and developing therapeutic proteins and other antibodies is through the use of the GlycoFi protein optimization technique. The alliance of the two firms did initiate a study on ten protein optimizations spread across a two-year research duration. The alliance did fuse GlycoFi technical platform into Lilly’s research programs with the aim of ideal manufacturing glycan required in the therapeutic protein (Lilly, global health , 2020). Noting that, several biologic drugs, safety, effectiveness, and dosage can be altered by increasing or decreasing particular glycan molecules.

The alliance further stated that Eli Lilly was to have equity shares in GlycoFi, finance all the cost of the study and make an upfront payment. In case Eli Lilly resorted to change and trade the alliance drugs, GlycoFi was to receive a more significant pay from goodwill and each compound used in the manufacture of drugs (Lilly, Select joint ventures,partnerships, and alliances, 2007). The alliance between the two firms is geared towards building a better tomorrow as their primary aim is to research and manufacture safe and effective antibodies.

Debrief (thoughts and opinions)

The alliance that the two-firm entered was primarily for research and development effective and safe of therapeutic and other antibodies. Commercialization of the project would mean a fresh frontier for both players, and GlycoFi is to receive payments for its compounds used. Despite receiving equity investment from Eli Lilly, payments received after commercialization would insinuate that GlycoFi was reaping big from the alliance. The payments are also for the royalty showing that the firm would remain financially stable throughout the two years. The alliance positive findings would also aid in benefiting millions of people around the globe in line with Eli Lilly’s mission. The alliance depicts a high degree of openness, moral charisma, and ethical manners that should be replicated by other firms while making alliances. Service delivery with the aim of a better tomorrow should be the driving force and not profits at the expense of humanity.

References

Glycofi. (2020, july 19). Glycofi inc. Retrieved from Glycofi: http://crunchbase.com

Lilly, E. (2007). Select joint ventures,partnerships, and alliances. glycofi press.

Lilly, E. (2020, july 17). general information obtained from the word wide web. Retrieved from eli lilly: http://www.elililly.com

Lilly, E. (2020, July 17). global health . Retrieved from Eli Lilly : https://www.lilly.com/social-impact/global-health